



1-1-2020

## Note from the Chief Technical Editor

Amy Seilliere

Follow this and additional works at: <https://scholarlycommons.pacific.edu/uoplawreview>



Part of the [Law Commons](#)

---

### Recommended Citation

Amy Seilliere, *Note from the Chief Technical Editor*, 51 U. PAC. L. REV. (2021).

Available at: <https://scholarlycommons.pacific.edu/uoplawreview/vol51/iss3/3>

This Front Matter is brought to you for free and open access by the Journals and Law Reviews at Scholarly Commons. It has been accepted for inclusion in University of the Pacific Law Review by an authorized editor of Scholarly Commons. For more information, please contact [mgibney@pacific.edu](mailto:mgibney@pacific.edu).

*Note from the Chief Technical Editor*

As Chief Technical Editor, I am delighted and honored to present the third issue of *The University of the Pacific Law Review*, Volume 51.

As *The University of the Pacific Law Review*'s Chief Technical Editor, my role is to examine the footnotes of each article to ensure compliance with the Harvard Bluebook and the McGeorge Style Manual. Each article undergoes multiple rounds of review—first by the staff writers, then by the primary editors, and finally by the Board of Editors. *The University of the Pacific Law Review* strives to output quality, thought-provoking articles and the accuracy of footnotes is an important part of this aim.

Today, the United States is the world's largest pharmaceutical market. This issue of Volume 51 explores important legal issues surrounding the rapidly growing pharmaceutical industry and its regulation. In his article, Professor Holman voices concerns about the way pharmaceutical companies use the patent system in the United States and offers suggestions to target the misuse of patents without impairing the patenting of pharmaceutical innovations. Professor Rose and Ms. Rice's article explores the Food and Drug Administration's recent Biosimilar Action Plan and analyzes its effectiveness in balancing innovation and competition in the United States. The remaining articles in this issue also contain meaningful discussions of the legal issues surrounding the pharmaceutical industry.

*The University of the Pacific Law Review*, Volume 51 would not be possible without the collaboration and efforts of the outstanding Board of Editors, with whom it has been a true pleasure to work. I owe my sincere thanks to DJ Mico, my proofreading counterpart, who is tasked with reviewing the content of each article to eliminate any grammatical or typographical errors. Also, I would like to specially thank Hayley Graves, our Editor-in-Chief, for her unmatched dedication to this publication. We genuinely hope that you enjoy this issue.

Amy Seilliere  
Chief Technical Editor  
*The University of the Pacific Law Review*,  
Volume 51